D'Amore Personal Injury Law, LLC
Serious Injury Lawyers Proudly Serving
Baltimore, Annapolis, & Washington, D.C.
This case involves a male infant with no known family history of hemophilia whose parents opted for circumcision. Following the procedure, the infant experienced persistent bleeding from both the circumcision and heel stick sites. Despite bringing this to the attention of hospital staff, the parents were reassured that this was normal. The infant was discharged without additional care instructions.
After discharge, the bleeding continued, prompting the parents to return to the emergency room. A blood clot test revealed abnormal results, yet the physicians did not attempt to stitch the circumcision site nor administer fluids or blood products. Eventually, a pediatric hematologist ordered factor studies, which indicated a severe Factor VIII deficiency. The bleeding began to improve, and the infant was discharged.
The following day, the infant became limp and refused to eat, leading to another emergency room visit. The child was found to be in critical condition, with pale blue skin and respiratory distress. A stitch was placed on the circumcision site, and the infant received blood transfusions. As a result of these complications, the infant developed impaired kidney function and a high-tier Factor VIII inhibitor.
Inhibitors are one of the worst outcomes for any hemophilia patient, as these patients have the greatest morbidities of this disease. The difficulty in hemophilia is that it is rare. Despite a very dedicated and motivated network of clinical and research centers, there is little prospective data, and the limited data out there is actively disputed. There are many risk factors related to inhibitor development and they are well known and summarized in every review article on this topic. In this case, intensive treatment, and treatment during a time of inflammation will be contributory. However, the patient was treated before SIPPET results were known so he likely received recombinant FVIII. Even that study, which is a global randomized multicenter study, is not conclusive to many people, but confirmed genetic risk factors (which were known and this patient may have) as an important risk factor. More importantly, it implied that recombinant FVIII was associated with a higher rate of inhibitors. I would say that >95% of new severe hemophilia patients in the USA got recombinant FVIII in 2013-14. In SIPPET, the recombinant group had an incidence of >40%. In general, we think that 30% of all severe hemophilia A patients will develop inhibitors and that 70% of those can be tolerated. In this case, I think that the delay to Dx is a true problem. I suppose that with more details, the care delivered could be questioned. But whether or not this boy would or would not have developed an inhibitor regardless of this history will always be debatable, even in the presence of risk factors.
D’Amore Personal Injury Law, LLC. is an award-winning law firm with decades of experience in fighting for their clients’ rights. If your child suffered complications after birth, contact us immediately.
This article is reprinted by permission from the original, which was produced by the Expert Institute. D’Amore Personal Injury Law works with the Expert Institute to identify and retain professionals with world class knowledge, experience, and credentials to testify on behalf of their personal injury clients. If you would like to learn more about the life changing results D’Amore Personal Injury Law has obtained for their catastrophically injured clients, please see our client results page.
Fill out the form below and we will contact you.
Or, give us a call at